Why the study?
Heart failure hospitalizations are associated with high mortality, and a comprehensive ambulatory, patient-centered approach may improve outcomes and reduce readmissions.
Does a multidisciplinary comprehensive ambulatory approach (GENICA protocol) reduce mortality and hospitalizations in patients with chronic heart failure?
Does a multidisciplinary comprehensive ambulatory approach (GENICA protocol) reduce mortality and hospitalizations in patients with chronic heart failure?
This study protocol outlines a prospective matched cohort study to evaluate whether a comprehensive, multidisciplinary ambulatory care program improves clinical outcomes in patients with chronic heart failure.
Introduction: Heart failure (HF) is a syndrome increasing worldwide, and literature shows that the hospitalizations are associated with greater mortality rates. A patient-centered method combined with optimized medical treatment and palliative care may improve HF outcomes, and some advocate a multifaceted approach to achieve a perfect management of chronic HF (CHF). Objective: The objective of this study was to present the study protocol of GENICA project which aims to optimize the ambulatory approach of CHF patients, and reduce their re-hospitalization, emergency readmission, and global death rate. Design: Prospective cohort including patients referred to HF consultation and collecting sociodemographic, clinical, and analytical variables among others. The outcomes will be mortality, re-hospitalization, and emergency readmission rates. The association between the independent variables and outcomes will be assessed by logistic regression. Comparison between GENICA patients and controls will be made by χ 2 test. Significance at p level of less than 0.05. Results: GENICA will offer a wide range of longitudinal data with evidence that will influence future healthcare of CHF patients at an ambulatory basis. Discussion: GENICA will provide practical evidence of real HF patient’s profile and develop workable decision algorithms, which will influence future ambulatory care of CHF. HF patients will be safer at home and will keep stability for longer periods, consuming less health resources and slow the progression of the disease. Being a matched cohort, GENICA benefits from an accuracy similar to that of randomized controlled trials, without the need to perform a rigorous allocation of the intervention. Being prospective there’s no problem about response bias. Conclusion: CHF should be approached with a multidisciplinary and multifaceted strategy privileging the outpatient setting, including home monitoring, and GENICA is the paramount protocol enabling this. GENICA may come to show health policy makers that the asset is not to divide and rule, but to converge strategies, therapies, and knowledge.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: